Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of BHV-1300 in Graves' Disease
Sponsor: Biohaven Therapeutics Ltd.
Summary
The purpose of this study is to determine if BHV-1300 is a safe treatment in participants with Graves' Disease and to explore its effect on disease-specific biomarkers.
Official title: An Open-Label Biomarker Study of BHV-1300 in Graves' Disease
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
15
Start Date
2025-08-21
Completion Date
2026-09
Last Updated
2026-03-12
Healthy Volunteers
No
Conditions
Interventions
BHV-1300
BHV-1300 is delivered subcutaneously (SC)
Locations (13)
Site-103
South Gate, California, United States
Site-100
Miami, Florida, United States
Site-104
Columbus, Georgia, United States
Site-106
Houston, Texas, United States
Site-101
Houston, Texas, United States
Site-105
Shavano Park, Texas, United States
Site-004
Fitzroy, Australia
Site-001
Kotara, Australia
Site-003
Melbourne, Australia
Site-010
Oaklands Park, Australia
Site-008
Parkville, Australia
Site-006
St Leonards, Australia
Site-002
Torquay, Australia